Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study-Reference-Cited by-同舟云学术

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

Published:2009-03 Issue:9667 Volume:373 Page:919-928
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Becker Richard C,Moliterno David J,Jennings Lisa K,Pieper Karen S,Pei Jinglan,Niederman Alan,Ziada Khaled M,Berman Gail,Strony John,Joseph Diane,Mahaffey Kenneth W,Van de Werf Frans,Veltri Enrico,Harrington Robert A

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Atlas of Heart Disease and Stroke,2004

2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients;BMJ,2002

3. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation;Yusuf;N Engl J Med,2001

4. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study;Lancet,1997

5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes;N Engl J Med,1998

Cited by 278 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™);Medicinal Chemistry Research;2022-09-02

2. The role of thrombin in the pathogenesis of atherosclerosis and its complications;Kardiologiia;2022-03-31

3. Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar;Current Problems in Cardiology;2021-10

4. Antiplatelet Agents;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26

5. Platelet physiology and pharmacology—relevant considerations for patient care;Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease;2021